Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Last trade$0.4068
Day change-$0.0027 (-0.66%)
Day range$0.382 – $0.416
Volume110,946
Market cap$8M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.98M
Price / earnings
—
Price / book
0.29×
Price / sales
1.29×
EV / sales
-3.48×
EV / EBITDA
0.24×
Profitability
Earnings per share
-$4.69
Return on assets
-294.68%
Return on equity
-332.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
8.02×
Quick ratio
8.02×
Cash ratio
7.72×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ENSC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.18M
$1.16M
$961K
$1.88M
$493.1K
$1.37M
$1.32M
$1.3M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$2.18M
$1.16M
$961K
$1.88M
$493.1K
$1.37M
$1.32M
$1.3M
Selling, general and administrative
$1.59M
$1.27M
$1.18M
$1.05M
$1.28M
$1.2M
$1.4M
$1.08M
Research and development
$83.08M
$2.47M
$3.35M
$3.61M
$2.95M
$1.92M
$1.89M
$3.8M
Total operating expenses
$84.68M
$3.74M
$4.52M
$4.66M
$4.23M
$3.12M
$3.29M
$4.88M
Operating income
-$82.5M
-$2.58M
-$3.56M
-$2.78M
-$3.74M
-$1.75M
-$1.97M
-$3.58M
Interest expense
-$3.15K
-$320
-$3.92K
-$5.38K
-$6.37K
-$3.16K
-$3.86K
-$10.75K
Income before taxes
-$82.11M
-$2.57M
-$3.56M
-$2.77M
-$3.73M
-$1.73M
-$1.95M
-$3.56M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$82.11M
-$2.57M
-$3.56M
-$2.77M
-$3.73M
-$1.73M
-$1.95M
-$3.56M
Net income attributable to common shareholders
-$82.32M
-$2.57M
-$3.56M
-$2.77M
-$3.73M
-$1.73M
-$1.95M
-$3.56M
EBITDA
-$82.49M
-$2.57M
-$3.56M
-$2.78M
-$3.74M
-$1.75M
-$1.97M
-$3.58M
Basic earnings per share
-$4.52
-$0.20
-$0.52
-$0.74
-$1.29
-$0.79
-$1.39
-$3.06
Diluted earnings per share
-$4.52
-$0.20
-$0.52
-$0.74
-$1.29
-$0.79
-$1.39
-$3.06
Recent news
Company coverage with links to the original publishers.
Ensysce Biosciences (NASDAQ: ENSC) shares surged 58.66% to $0.63 on Friday after the company announced a strategic review of alternatives aimed at enhancing shareholder value. The Board is exploring partnerships, licensing arrangements, or asset sales to advance its proprietary TAAP and MPAR platforms for safer opioid medicines.
Several companies are transitioning from strategic announcements to operational execution. Kraig Biocraft Laboratories has begun production of recombinant spider silk and received National Geographic cover feature. Rackspace and Palantir announced a strategic partnership to deploy enterprise AI in production environments. Ensysce Biosciences initiated a formal strategic review to explore partnerships and enhance shareholder value.
DelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developments include FDA orphan drug designation for Adolore BioTherapeutics' gene therapy, positive Phase IIb results for Dogwood Therapeutics' Halneuron, and Phase III publication of Vertanical's VER-01 for chronic low back pain.
Ensysce Biosciences advanced multiple clinical initiatives in Q2 2025, including launching a Phase 3 trial for PF614, completing enrollment in an overdose prevention study, and receiving a patent notice for its OUD program.
Ensysce Biosciences reported Q2 2025 results, advancing its PF614 opioid program to Phase 3 and achieving milestones in overdose-protection studies. The company reported a narrower GAAP loss of $(0.79) per share, with revenue primarily from federal grants.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.